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Abstract
Background: Age-related bone loss is asymptomatic, and the morbidity of osteoporosis is secondary to the
fractures that occur. Common sites of fracture include the spine, hip, forearm and proximal humerus. Fractures at
the hip incur the greatest morbidity and mortality and give rise to the highest direct costs for health services. Their
incidence increases exponentially with age.
Independently changes in population demography, the age - and sex- specific incidence of osteoporotic fractures
appears to be increasing in developing and developed countries. This could mean more than double the expected
burden of osteoporotic fractures in the next 50 years.
Methods/Design: To assess the predictive power of the WHO FRAX™ tool to identify the subjects with the
highest absolute risk of fragility fracture at 10 years in a Spanish population, a predictive validation study of the
tool will be carried out. For this purpose, the participants recruited by 1999 will be assessed. These were referred to
scan-DXA Department from primary healthcare centres, non hospital and hospital consultations. Study population:
Patients attended in the national health services integrated into a FRIDEX cohort with at least one Dual-energy
X-ray absorptiometry (DXA) measurement and one extensive questionnaire related to fracture risk factors.
Measurements: At baseline bone mineral density measurement using DXA, clinical fracture risk factors
questionnaire, dietary calcium intake assessment, history of previous fractures, and related drugs. Follow up by
telephone interview to know fragility fractures in the 10 years with verification in electronic medical records and
also to know the number of falls in the last year. The absolute risk of fracture will be estimated using the FRAX™
tool from the official web site.
Discussion: Since more than 10 years ago numerous publications have recognised the importance of other risk
factors for new osteoporotic fractures in addition to low BMD. The extension of a method for calculating the risk
(probability) of fractures using the FRAX™ tool is foreseeable in Spain and this would justify a study such as this to
allow the necessary adjustments in calibration of the parameters included in the logarithmic formula constituted
by FRAX™.
Background
Epidemiology of osteoporotic fractures
Osteoporosis is an asymptomatic disease until it is com-
plicated by a bone fracture occurring without trauma or
after a minimum trauma. It is the most common bone
disease in humans and represents an important health
care problem in developed countries. The high inci-
dence of osteoporosis worldwide and its main complica-
tion, osteoporotic fractures, also known as fragility
fractures, have been recognised for more than 20 years
[1]. One of the first meta-analyses on fracture risk pub-
lished in 1996 demonstrated the association between
bone mineral density (BMD) and the risk for osteoporo-
tic fracture [2].
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ing an osteoporotic fracture during the remainder of her
life (the most frequent are; vertebral, forearm, humerus
or hip) surpasses even the risk of having breast cancer,
with this probability being approximately 40% higher in
developed countries and very close to the risk of coron-
ary disease in the same countries [3].
According to the recent guidelines by the American
College of Physicians for the screening of osteoporosis
in males, this disease is considered to be underdiag-
nosed and under-treated, perhaps due to the relatively
lower frequency. A 60-year-old white man has a 25%
risk of having an osteoporotic fracture during his life-
time, with even more severe consequences than in
women [4]. Indeed, the post-hip fracture mortality at
one year in men is double that in women [4]. The influ-
ence of fragility fractures on the quality of life of both
men and women has also been widely reported [5].
According to data estimated in subjects over the age
of 50 years in Europe in the year 2000, 620,000 new hip
fractures, 575,000 shoulder fractures, 250,000 proximal
humerus fractures and 620,000 symptomatic vertebral
fractures were reported, representing almost 35% of the
fractures described in the world [6]. The direct costs of
osteoporotic fracture in Europe are of around a total of
36 billion Euros per year [7].
The greatest clinical relevance of osteoporosis is consti-
tuted by osteoporotic fractures, and these are implicated
i nt h ei n c r e a s ei nm o r b i m o r t ality and loss of quality of
life attributable to this disease. Thus, attention must be
focused on the identification of patients with a high risk
of fragility fracture [8], than on the identification of those
with osteoporosis, diagnosed exclusively by densitometry.
Although BMD (measured by densitometry) is an
important component of fracture risk, several other risk
factors have also been demonstrated to greatly contri-
bute to the risk of fracture and should be taken into
account when performing a global evaluation of risk [8].
Clinical determinants of osteoporotic fracture
In the last years different studies have been carried out
with the aim of identifying the clinical risk factors which
m a yb eu s e di nt h es e a r c hf o rt h e r a p e u t i cs t r a t e g i e s ,
with or without the use of densitometry [9].
The last version of the European guidelines for the
diagnosis and treatment of osteoporosis in postmeno-
pausal women published in 2008 [10] proposes the
strategy of evaluation together the results of densitome-
try and clinical risk factors of fracture to decide which
diagnostic and therapeutic interventions to implement.
The FRAX ™ tool, a useful tool for clinical practice
In 2008, the WHO published a new promising tool for
the evaluation of absolute risk of fragility fracture: the
FRAX™ tool [11], WHO fracture risk assessment tool.
This is a scale including 11 of the clinical risk factors
which have demonstrated a strong association with the
incidence of fracture in previous studies according to
the WHO experts. Factor number 12 in this scale also
includes a single value of Dual-energy X-ray absorptio-
metry (DXA) central bone densitometry: the T-score of
the femoral neck. An introducing these data of a patient
provided in the form of the FRAX™ website, an indivi-
dualised calculation of the percentage of prediction of
absolute risk of: (a) major osteoporotic fracture (clinical
vertebral, hip, forearm or humeral fracture) and (b) hip
fracture in the following 10 years may be made [11].
To develop the logarithmic formula of FRAX™,w e r e
included parameters from different European cohorts
from the EVOS study focused on vertebral fractures
[12]. As representatives of the Spanish population were
included people from Oviedo and other three Spanish
cities. However, they had very low rates of response: in
some cases were less than 8%, with a total number of
subjects potentially insufficient to be representative of
Spanish population [13].
On the other hand, it should be pointed out that as
recommended in the description of the FRAX™ tool,
this scale should be developed and validated in each
country. Cost-effectiveness studies are also recom-
mended with the data from each country to obtain an
approximation of the cost which each country is willing
to accept as reasonable for the prevention of fragility
fractures.
It is therefore reasonable for the first step before the
generalised use of the FRAX™ scale in the medical
offices of our country to carry out the validation of this
scale in a larger cohort made up of the patients usually
attended at the different health care levels in which
diagnostic; treatment and follow up interventions for
osteoporosis are undertaken. On the other hand, recent
evidence [14-17] also recommend the evaluation of
other risk factors related to low mass and risk of fragi-
l i t yf r a c t u r ea n dn o tc o n s i d e r e di nt h eF R A X ™ tool
when assessing fracture risk such as the presence of
chronic obstructive pulmonary disease (COPD), the use
of some drugs such as aromatase inhibitors (increasingly
more frequent in women treated for breast cancer),
daily calcium intake and usual physical activity which
are related to bone mass and risk of fragility fracture.
Falls and fragility fractures
Fragility fractures are defined as those which occur after
non major impact produced by a fall from a height of
less than that of the patient with no added inertia to
that of the displacement of its foot when walking.
Since more than 20 years ago studies have demon-
strated the importance of falls on the incidence of new
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tion between the number of falls and fracture. This
association is even more important in patients over the
age of 75 years than the classical association described
between osteoporosis and fracture [16]. Different vari-
ables related to the greater risk of falls have also been
reported such as factors of the individuals themselves
(muscular strength of the lower extremities, equilibrium
or postural competence, difficulties in vision, cognitive
deterioration), purely environmental factors (home light-
ing, rugs, pets...) and iatrogenic factors (different groups
of drugs, drug combinations) [18-21].
Despite these evidence on the potential influence of
falls on the occurrence of fragility fractures, they have
not been included as risk factors in the FRAX™ tool for
the determination of absolute fracture risk at 10 years,
probably due to the publication of studies with contra-
dictory long term results which impede consistent estab-
lishment of their association.
The importance of being able to determine the asso-
ciation between the number of falls and the appearance
of fragility fracture may be established by the possibility
of their prevention, thereby reducing the risk of falling.
Different studies have presented good results with differ-
ent training techniques and ar e c e n tC o c h r a n er e v i e w
[22] provides measures of the potential benefit of inter-
ventions such as programmes of multidisciplinary detec-
tion and intervention (RR 0.73;CI 95%: 0.63-0.85),
muscular strengthening and balance retraining (RR 0.80;
CI 95%: 0.66-0.98), evaluation and modification of risks
at home (RR 0.66; CI 95%; 0.54-0.81), withdrawal of psy-
chotropic drugs (RR 0.34; CI 95%: 0.16-0.74) and a 15-
week intervention of Tai Chi group exercises (RR 0.51;
CI 95%: 0.36-0.73) among others.
The latest guidelines published in our country recom-
mend intervention related to the risk of fall in subjects
with osteoporosis according to a maximum grade of evi-
dence (SEIOMM Guidelines 2008, AATRM Guidelines)
[23,24].
The high incidence of falls in the elderly (30% of sub-
jects over the age of 65 years living at home fall every
year) [22], as well as the associated morbidity and the
tests available demonstrate the relevance of a study such
as this to establish their association and determine the
need for their inclusion as important and preventable
risk factors in tools such as FRAX™ to assess the abso-
lute risk of osteoporotic fractures.
FRAX™ is a tool which is evolving and in the future
may become a commonly used tool in medical centres
in our country, especially in Primary Care (PC) in which
the greatest number of subjects with osteoporosis is
attended and where programmes of prevention of osteo-
porotic factors may be carried out. This is another argu-
ment reinforcing the need for urgent validation of this
scale in our country, and it is the main objective of this
study.
Objectives
Main objective
To determine the predictive validity of the WHO
FRAX™ risk scale to identify subjects with the greatest
absolute risk of fragility fracture in the next 10 years in
a Spanish population in a clinical cohort designed to
promote the study of different risk factors of presenting
osteoporotic fractures.
Secondary objective
To analyse the association between clinical and environ-
mental risk factors (number of falls, exposure to drugs,
dietary calcium intake) and the occurrence of osteo-
porotic fracture in a susceptible Spanish population.
Methods/Design
Study of predictive evaluation of a tool to assess the risk
of osteoporotic fracture through the follow up of a
cohort initiated in 1999.
Study population and enrolment procedures
This multicentre study is carried out by family practi-
tioners and other specialists who refer patients to the
same reference centre for undertaking BMD. The cri-
teria for referral follow the recommendations of the
WHO of not performing a population screening but to
select cases among those of greatest risk of having
osteoporosis and subsequent osteoporotic fractures or
the follow up and control of patients already receiving
treatment.
The FRIDEX cohort (Factors of fracture risk and cen-
tral bone densitometry). This cohort is constituted of
men and women referred by general practitioners and
specialists for undergoing central bone densitometry by
Dual-energy X-ray absorptiometry (DXA) for the initial
study of osteoporosis or treatment follow up, who
accept to answer an extensive questionnaire on risk fac-
tors (RF) for osteoporotic fracture (family history of
osteoporosis and hip fracture, clinical risk factors and
lifestyle habits related to diet and toxic substances) [see
Table 1]. This cohort was initiated in 1999 at the Bone
Densitometry Unit of the Department of Nuclear Medi-
cine of the University Hospital Vall d’Hebrón in Barce-
lona and at the end of 2009 had included 25,783
persons of both genders who had undergone a total of
41,849 DXA and questionnaires on RFs.
Since the beginning of the study verbal informed con-
sent to participate in the cohort was obtained from all
the patients and an extensive questionnaire on clinical
risk factors was carried out. The data collected is stored
in a specific database (DB) for this cohort.
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reference centre and a questionnaire on risk factors
(QRF) for osteoporotic fractures is given during the visit
and anthropometric parameters are determined. Ten
years after the first QRF and DXA the patients are
asked to answer a phone survey (See additional file 1) to
know the evolution of the study variables and outcomes
(fragility fractures).
Study population
Urban setting. Primary care (PC), extrahospitalary (E)
and hospital specialties (H).
Integrants of the FRIDEX cohort. Randomised sample
(simple computerised randomisation stratified by sex) of
men and women from 40 to 90 years of age in the FRI-
DEX cohort for 10 years since the baseline DXA and
QRF. At the end of 2009 this sub-cohort included 5,813
persons recruited from January 1 to December 31, 2000.
Eligibility Criteria
A total of 3,684 subjects were randomised, 9.3% being
males to maintain the original proportion of the global
study cohort.
Inclusion criteria
The study subjects were Caucasians, ≥ 40 and ≤ 90 years
of age at the time of inclusion in the FRIDEX cohort,
understood and spoke the Spanish language, were able to
respond to the initial and/or follow up telephone
questionnaire (TQ) and accepted to participate in the
study providing the corresponding informed consent.
Physically or psychically handicapped patients were
included if the relatives or care providers accepted to
answer the TQ.
Exclusion criteria
Subjects < 40 or > 90 years of age at the time of the first
DXA and QRF were excluded since FRAX™ does not
allow the calculation of the adjusted risk outside this
age range. Patients with physical or psychic limitations
impeding their participation and whose relatives did not
accept to respond to the TQ were excluded as were
those with Paget’s disease, cancer with bone involve-
ment or disease which may simulate osteoporosis (i.e.
myeloma). Patients of ethnic groups other than Cauca-
sian were not included since other studies have demon-
strated different risk characteristics. Patients not
providing consent to respond to the TQ and those with-
out a telephone to contact or did not respond after 3
calls made at different times according to the procedure
manual were also excluded from the study.
Sample Size (figure 1):
For the main objective (predictive validation of
FRAX™ it has been calculated that a sample of 1,070
individuals are needed in a bilateral contrast to guaran-
tee that the sample estimates the percentage of inci-
dence of new fractures with a precision of 3%. If an
annual loss rate of 1% during the 10 years of follow up
of the study is considered, a sample of 1,177 subjects is
required. In the pilot study carried out in April 2009 in
a randomised sample of 149 cases with three telephone
calls / person, 47 persons could not be contacted
(31.5%). One hundred two (68.5%) were contacted, of
which 3 (4.9%) living patients and the relatives of 2 dead
patients refused to participate. Cases receiving anti-
osteoporotic drugs and/or those with cancer (35 people)
and 6 males were excluded. Information was obtained
on data at 10 years in 97 of the 149 cases. A total of
3,664 individuals should therefore be contacted, thus
our population of 5,813 subjects potentially eligible
guarantees the necessary sample size.
Finally, in the pilot study of 149 patients and after
fulfilling the exclusion criteria we obtained a sample of
56 (37.6%) of the 149 cases. With more conservative
calculations, a maximum of 3,056 subjects should be
contacted plus 20% for safety. Thus 3,664 persons
should be contacted, therefore our originally recruited
population of 5,813 subjects greater than 40 years of
age included in the cohort until the end of 2000 suffi-
ciently guarantees the necessary sample size. Conse-
quently, 3,664 subjects were randomly selected from
the 5,813 patients included in the cohort during the
year 2000.
Table 1 Total FRIDEX (2000-2010 years) cohort
description
Total Men Women
Cases 25,783 2,349 23,434
N (SD) N (SD) N (SD)
Age 61.2 (10.2) 65.0 (10.8) 60.8 (10.1)
Weight 68.1 (12.2) 75.3 (13.3) 67.4 (11.9)
Height 155.6 (7.4) 165.7 (7.2) 154.6 (7.4)
N (%) N (%) N (%)
Parental Osteoporosis or
Fracture
Yes 4,220
(16.4%)
153 (6.5%) 4,067
(17.4%)
No 21,524
(83.6%)
2,192
(93.5%)
19,332
(82.6%)
Parental Hip Fracture Yes 166 (6.3%) 10 (2.6%) 156 (6.9%)
No 2,462
(93.7%)
372
(97.4%)
2,090
(93.1%)
Previous Fractures Yes 6,865
(26.6%)
837
(35.6%)
6,028
(25.7%)
No 18,918
(73.4%)
1,512
(64.4%)
17,406
(74.3%)
Current Prescriptions Yes 13,928
(54.0%)
1,048
(44.6%)
12,880
(55.0%)
No 11,855
(46.0%)
1,301
(55.4%)
10,554
(45.0%)
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Ordering will be performed using randomised numbers
for each month and the calls will be made in this order
until the required number is achieved. The approximate
calculation is of 317 cases / month with a range from
190 to 395 cases in the different months of 2000, and
the calls will be made until the figure calculated per
month is met.
Overview of outcome measurements
Data collection
The baseline variables of both BMD and QRF were col-
lected at the time of inclusion (2000). The follow up
variables (fractures and incidental falls) will be collected
by telephone questionnaire (TQ) during 2010 and the
beginning of 2011 to complete the 10 years of follow
up. The TQ will collect data regarding the fractures
occurring from the time of inclusion until the date of
t h eT Qa sw e l la so t h e ri n f o r m a t i o no nk n o w nf a c t o r s
of fracture risk.
Baseline variables
These include variables related to the patient: Demo-
graphic (date of birth, sex), anthropometric (weight,
height, body mass index).
BMD measurement will be determined by central
DXA according to the 2004 and 2007 recommendations
of the International Society for Clinical Densitometry
ISCD (available at: http://www.iscd.org/Visitors/posi-
tions/OfficialPositionsText.cfm) for the interpretation of
the results using a Lunar GE model “Prodigy Advance”
densitometer with 11.4 software and with BMD and
T-score determination with NHANES III references.
The densitometry diagnostic criteria used are the 1994
WHO criteria which classify the results into 3 groups
according to the levels of BMD values of the femoral
Figure 1 FLOW CHART study. Participant’s selection.
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between -2.5 and -1) and osteoporosis (T-score ≤ -2.5).
Additional file 1 shows the clinical factors of fracture
risk analysed with the structured questionnaire (QRF),
dietary intake of calcium and drugs use.
The estimated absolute risk of fracture at 10 years
according to the FRAX™ tool is determined through
the official web site (available at: http://www.shef.ac.uk/
FRAX). The calculations of probability of fracture with
or without the T-score will be analysed in parallel by
two blinded investigators (patients anonymised and
assigned an alphanumeric code). On the appearance of
any difference a third and fourth blinded investigator
will analyse the results and will recalculate the case.
Follow up variables
These variables include the appearance of incidental
fracture in the last 10 years (dependent variable): the
telephone questionnaire will be carried out with a tele-
phone call made after 10 years of follow up. All the frac-
tures will be confirmed through medical records and/or
consultations to the health care centres after receiving
authorisation from the participants. In all cases the fol-
low up at 10 years will be completed in these subjects.
In cases of death, the data related to the cause of death
and the appearance of fractures will be requested from
the relatives and by record checking.
The number of falls during the last year will be deter-
mined with the TQ. Review of the literature has shown
different ways to analyse the falls occurring in the study
subjects. The most frequently used method is consid-
ered in this study which asks about the number of falls
during the year prior to the interview and whether a
fracture was produced in any of the falls. Other variables
to be collected during this period are: the appearance of
important diseases, the taking of osteopenic drugs and
the use of walking aids. Additional file 2 shows the tele-
phone questionnaire.
Analysis plan
The characteristics of the population will be described
according to univariate descriptive analysis. Simple com-
parisons of the baseline characteristics will be made
among the participants and non participants of the
cohort. The Chi-square test will be used to evaluate the
association between qualitative variables. The Student’s
t-test or, if necessary, its non parametric equivalent, the
Mann-Whitney U test, will be implemented to evaluate
the differences in the distribution of a quantitative vari-
able according to the categories defined by a binary expo-
sure. To assess the differences in the distribution of a
quantitative variable according to the categories defined
by a categorical variable with more than 2 categories,
ANOVA analysis of variance or its corresponding non
parametric test (Kruskal-Wallis) will be used.
For the predictive validation of the FRAX™ tool, the
appearance of the first fracture occurring during the fol-
low up period will be taken into account. The validation
of the results obtained with the FRAX™ will be per-
formed with the Hosmer-Lemeshow test and the calcu-
lation of the ROC curve. This test divides the
participants into groups (normally 10) based on their
estimated risk of fracture (FRAX™) and confirms that
each group presents a number of cases of incidental
fractures adjusted to the predicted number. On the
o t h e rh a n d ,t h eR O Cc u r v ec o n s i d e r st h es c a l eo f
FRAX™ risk as a diagnostic test of the presence of
future fractures and as such leads to different calcula-
tions of sensitivity and specificity changing the cut off
point selected. Finally, both probabilities (sensitivity and
the complementary of specificity, or 1- specificity) will
be graphically represented the curve. The shape of the
curve is a visual indicator of the quality of the diagnostic
test.
To know the distribution of the factors associated
with fracture according to age and sex, bivariate combi-
nations will be used with the Chi-square test among
categorical variables and the Student’s test among quan-
titative and categorical variables. To model the number
of fractures occurring in our dataset which is, in fact, a
count over time, Poisson regression will be used, which
is what is precisely required for this type of variables
and was used for the creation of the FRAX™ scale. All
the statistical tests will be undertaken with a confidence
interval of 95% and with the use of the 17th or latest
version available of the SPSS statistical package.
Study limitations, potential limitations and biases
Since the FRIDEX cohort is constituted by subjects
requiring a DXA scan (according to their physician), it
likely that the recruited population will be at a baseline
risk greater than that of the general population. None-
theless, descriptive analysis of the population of this
cohort indicates that the percentage of 32.3% of persons
with densitometry osteoporosis is very similar to that
reported in the literature for women of 50 years of age.
Our results may therefore be extrapolated to a popula-
tion in which the physician is evaluating the risk of low
bone mass or fracture (case finding) which is, further-
more, the population recommended for investigation by
the WHO.
The QRF used includes the variables of the FRAX™
scale and is complemented by the follow up telephone
questionnaire on fractures, falls and new medications
prescribed as well as diseases developed in the last
10 years.
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beginning of the FRIDEX cohort. Therefore, it may only
be considered as an outcome variable in the subgroup
of cases with incidental fractures posterior to the collec-
tion of this variable. Nonetheless, according to the opi-
nion of the external assessor and the research team, this
variable is highly related to the risk of fracture and thus,
should be collected and taken into account in this study.
To minimise the effect of possible losses which may
imply bias (given the morbimortality associated with frac-
tures and the possible dropouts over 10 years), notable
increases in the sample size have been considered neces-
sary such as the cases to be localised among those with a
contact telephone number. We believe that this will mini-
mise the losses to follow up or refusal to participate for
several reasons: information will be collected by telephone
to avoid the difficulties of post questionnaires, which have
low response rates in our setting; in addition the partici-
pants in the FRIDEX cohort had already accepted to parti-
cipate in the QRF and almost all of the persons contacted
in the pilot study accepted to answer follow-up survey.
T h e r em a yb eab i a si nt h ec o l l e c t i o no ft h ei n f o r m a -
tion on incidental fractures which is collected based on
the patient self-report. Nevertheless, in this study all the
new fractures detected will be contrasted with the corre-
sponding medical reports or by consultation with the
physicians. Thus silent vertebral fractures will be scar-
cely detected but the symptomatic vertebral fractures,
which are those included in the prediction of the
FRAX™, will be collected. In addition, this is the usual
method used in large epidemiological studies. The possi-
ble limitations inherent to data collection by telephone
will be minimised with interviewer training among per-
sonnel with health care background through the
improvement detected in the pilot study and by the
incorporation of potential improvements thereafter.
The study has been approved by the ethical committee
of the Clinical Research Ethics Committee of the Vall
d’Hebron University Hospital (Barcelona, Spain). Addi-
tional file 3 shows the timing of the project.
Discussion
Since more than 10 years ago numerous reports have
recognised the importance of other risk factors for new
osteoporotic fractures in addition to low BMD. This
new evidence has modified the conception of the utility
of BMD as the gold standard or as an added element
for decision making in the management of osteoporosis
in primary health care settings.
The FRAX™ tool was published by the WHO in 2008
and was created to establish a calculation of the probabil-
ity of absolute risk of osteoporotic fracture at 10 years.
This was initially based on the analysis of thousands of
person included in several cohorts in Europe [12,13].
Since its publication this tool has also been used to know
the risk of fracture in other population cohorts in Europe,
the United States of America, Canada, and Japan [25-30].
Likewise, since its publication this tool has undergone new
adjustments and calibrations for different populations [30].
On the other hand, some studies have also recently been
published, in which the cases of fracture estimated or
expected by the FRAX™ tool were significantly lower
than the cases of incidental fractures actually observed in
the 10 years of follow up [31].
In the case of the Spanish population included in the
FRAX™ tool, there are some doubts as to their repre-
sentativeness because of the scarce response of original
study and scarce global number of patients included
[12,13], which could represent problems of external
validity and should be contrasted with new studies of
large cohorts over long periods of follow up to allow the
establishment of epidemiological relationships adjusted
to each population.
The extension of a method for calculating the risk
(probability) of fractures using the FRAX™ tool is fore-
seeable in Spain similar to what is occurring in other
countries and this would justify a study such as this to
allow the necessary adjustments in calibration of the
parameters included in the logarithmic formula consti-
tuted by FRAX™.
From the point of view of validation and economic
analysis of the FRAX™ tool, the National Osteoporosis
Guideline Group (NOGG) has recently published a cal-
culation with FRAX™ which takes cost-effectiveness to
avoid a new fracture in a population in the United King-
dom into account [15]. This is one of the first countries
to publish studies on the economic cost which means
the willingness to pay and cost-effectiveness to avoid a
new fracture in its population. These calculations have
been based on the calculation of fracture risk using the
FRAX™ tool and determined clinical risk factors.
It can be expected that other counties will establish
the same parameters with economic evaluation derived
from the application of the FRAX™ tool. A study of the
diagnostic validation of the FRAX™ tool is necessary as
the first step to establish the criteria of cost-effectiveness
and the number of cases to treat to avoid the appear-
ance of new osteoporotic fractures.
Studies in large cohorts over long periods of follow up
have allowed epidemiological associations to be estab-
lished, and although numerous studies have demon-
strated the independent association of clinical and
environmental risk factors with low BMD, some associa-
tions with fractures in populations in different geogra-
phical zones are pending thus, the need for extensive
epidemiological studies in the Spanish population.
One of the few studies published with the FRAX™ tool
in Spain did not provide new knowledge on the idealness
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such as the present which will allow the necessary calibra-
tions and adjustments of the parameters included in the
logarithmic formula constituted by the FRAX™.A tt h e
same time, the scientific community requires a relatively
easy and agile system to determine when a DXA should
be requested and/or when treatment for osteoporosis
should be initiated based on reliable predictive models
similar to those already implemented in the daily routine
for the prevention of cardiovascular events.
The WHO has recommended that prospective studies
should be performed with this methodology in our
population. This is therefore a great opportunity to vali-
date and contribute to the determination of its true uti-
lity among the collective of physicians, especially in
Primary Care, and in the population by focusing on
interventions in the cases of greatest risk of fracture.
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